IP Library › Granted Patent US 12,138,322
Granted Patent B2
US 12,138,322 · App. 18/610,095 · Granted Nov 12, 2024

Method of preventing the development of melanoma

Inventors: Peter Novak (Sunny Isles Beach, FL); Max Temnik (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
Assignee: Vector Vitale IP LLC
A61K51/0476A61K31/164A61K33/30A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,138,322
App. No.
18/610,095
Granted
Nov 12, 2024
Kind
B2
Abstract

A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64 Zn e (Asp) 2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64 Zn e (Asp) 2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Claims (8)

1. A method of reducing melanoma tumor growth of a primary melanoma in a patient in need thereof, comprising suppressing tumor growth of the primary melanoma in said patient by administering a pharmaceutical composition comprising a therapeutically effective amount of 64 Zn e (Asp) 2 , wherein from 0.2 μg/kg patient weight/day to 2000 mg/kg patient weight/day of 64 Zn e (Asp) 2 is administered to said patient and wherein the 64 Zn e (Asp) 2 is at least 80% 64 Zn.

2. The method of claim 1 , wherein the composition is an aqueous solution.

3. The method of claim 1 , wherein 64 Zn e (Asp) 2 comprises 2 molecules of aspartic acid.

4. The method of claim 1 , wherein the composition is administered once a day.

5. The method of claim 1 , wherein the composition is administered more than once a day.

6. The method of claim 1 , wherein the composition further comprises deuterium-depleted water as a solvent.

7. The method of claim 1 , wherein the composition is administered intratumorally or intravenously to said patient.

8. The method of claim 1 , wherein the composition is administered intravenously to said patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 068674/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 068674/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: TEMNIK, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 067823/0507 →
Continuity (4)
Continuation 18232013 · Aug 9, 2023
Continuation 17969297 · Oct 19, 2022
Continuation 16692584 · Nov 22, 2019
Related Publication 20240216552A1 · Jul 4, 2024
Cited By (1)
US 12,734,240